Nucleic Acids in Human Glioma Treatment: Innovative Approaches and Recent Results by Catuogno, S. et al.
Hindawi Publishing Corporation
Journal of Signal Transduction
Volume 2012, Article ID 735135, 11 pages
doi:10.1155/2012/735135
Review Article
NucleicAcids in Human GliomaTreatment:
Innovative ApproachesandRecentResults
S.Catuogno,1,2 C.L.Esposito,1 C.Quintavalle,2 G.Condorelli,1,2 V. de Franciscis,1
and L. Cerchia1
1Istituto per l’Endocrinologia e l’Oncologia Sperimentale del CNR “G. Salvatore”, Via Pansini 5,
80131 Naples, Italy
2Dipartimento di Biologia e Patologia Cellulare e Molecolare, University of Naples “Federico II”, Via Pansini 5,
80131 Naples, Italy
Correspondence should be addressed to V. de Franciscis, defranci@unina.it and
L. Cerchia, cerchia@unina.it
Received 10 January 2012; Accepted 29 February 2012
Academic Editor: Juan-Carlos Martinez Montero
Copyright © 2012 S. Catuogno et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gliomasarethemostcommonprimarycentralnervoussystemtumorswithadismalprognosis.Despiterecentadvancesinsurgery,
radiotherapy, and chemotherapy, current treatment regimens have a modest survival beneﬁt. A crucial challenge is to deliver
drugs eﬀectively to invasive glioma cells residing in a sanctuary within the central nervous system. New therapies are essential,
and oligonucleotide-based approaches, including antisense, microRNAs, small interfering RNAs, and nucleic acid aptamers, may
provideaviablestrategy.Thankstotheiruniquecharacteristics(lowsize,goodaﬃnityforthetarget,noimmunogenicity,chemical
structures that can be easily modiﬁed to improve their in vivo applications), these molecules may represent a valid alternative to
antibodies particularly to overcome challenges presented by the blood-brain barrier. Here we will discuss recent results on the use
of oligonucleotides that will hopefully provide new eﬀective treatment for gliomas.
1.Introduction
Glioma is the most common primary brain tumor, generally
characterized by highly inﬁltrative nature, high malignancy,
andpoorclinicaloutcome.Despitegreatadvancesinsurgical
techniques, radiotherapy, and chemotherapy, the prognosis
of this tumor remains poor [1, 2].
Histologically gliomas are classiﬁed as astrocytomas,
oligodendrogliomas, or ependymomas depending on cell
morphology[3–7].Genomicanalysisofgliomashasrevealed
diﬀerent subtypes that show distinct patterns of mutations,
copy number alterations, and gene expression [8, 9]. On the
basis of the grade of malignancy, as established by the World
Health Organization [2], they can be further categorized as
low grade (grade I and grade II) and high grade gliomas
(gradeIIIandgradeIV).GradeItumorsarerelativelybenign
and show the best prognosis. Grade II tumors contain some
anaplastic cells and can progress to higher grade tumors.
GradeIIItumorsshowahighdegreeofanaplasiaandmitotic
activity and are often rapidly fatal. The most aggressive
type of glioma is the grade IV astrocytoma or glioblastoma
multiforme(GBM).Thisisahighlyanaplasticandmalignant
tumor which is almost always fatal because of its resis-
tance to radio—and chemotherapy. To date, antibody-based
approaches have been developed for in vivo applications but,
in most cases, adequate sensitivity has not yet been reached;
they show toxicity in vivo and are not able to eﬃciently
cross the blood-brain barrier (BBB). Promising alterna-
tive approach to antibodies is now represented by RNA
and DNA oligonucleotides, including antisense (AS-ODN),
microRNAs (miRNAs), small interfering RNAs (siRNAs),
and nucleic acid aptamers (see Figure 1). Among them, only
AS-ODNs are already in clinical development [10]. The
most advanced is a phosphorothioate-modiﬁed AS-ODN
(Trabedersen, AP 12009, Antisense pharma) directed against
the transforming growth factor-beta 2( T G F - β2), a protein
that is massively produced by high-grade gliomas and pro-
motes tumor cell proliferation, angiogenesis, invasion and2 Journal of Signal Transduction
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Figure 1: Mechanism of action of nucleic acids. AS-ODN, miRNAs, and siRNAs act on the mRNA preventing proteins translation. Nucleic
acid aptamers fold into complex tridimensional shapes that allow direct binding to target protein.
metastasis. Thus, inhibiting TGF-β2 production, Trabeder-
sen exerts multiple antitumor eﬀects. To bypass the BBB,
this AS-ODN has been administrated intratumorally using
a single intratumoral catheter linked to a portable pump.
On the basis of the positive results obtained in phase I
and II clinical trials, in which Trabedersen resulted safe
and well tolerated in patients with high grade gliomas, the
oligonucleotide is currently in phase III [11].
Even if their clinical development is still being realized,
miRNAs, siRNAs, and aptamers are emerging as innovative
tools with an extraordinary potential for the treatment of
diﬀerent human diseases including glioma (see Table 1). In
this paper we will focus on recent progresses and challenges
of these three classes of oligonucleotides, with a major
emphasis for those molecules that show great potential for
clinical development.
2. Oligonucleotides versusProteins
Oligonucleotides show many advantages over proteins as
diagnostics and therapeutics. Indeed, they are entirely chem-
ically synthesized, resulting in an easier production, in which
complex manufacturing processes are avoided. Moreover,
they can achieve high target selectivity, are suﬃciently stable,
and can be readily chemically modiﬁed to further enhance
their stability, bioavailability, and pharmacokinetics. In this
regard, the most eﬀective modiﬁcations to reduce in vivo
nuclease degradation are substitutions at the 2 -ribose of the
pyrimidines with ﬂuoro (2 -F-Py) or amino groups, but also
introductions of 2 -O-Metyl purines [12–14], changes in the
internucleotide linkages and in the nucleobases (such as the
use of phosphorothioate) and capping at the oligonucleotide
3 -terminus have been successfully adopted [15]. Further,
the use of locked nucleic acids, containing a methylene
bridge to connect the 2 -O to the 4 -C, increases the stability
of base pairing, stabilizing the duplex, and enhancing the
resistance to nuclease [16–18]. The addition of polyethylene
glycol (PEG) and other moieties can be used to increase
oligonucleotides size enhancing their bioavailability and
pharmacokinetic properties [19, 20].
One particularly attractive feature of oligonucleotides
is that they are much less immunogenic than proteins.
Indeed antibodies toward synthetic oligonucleotides are not
generally produced and, the innate immune response by toll
like receptors against nonself RNAs can be bypassed by the
replacement of only uridines with their 2 -ﬂuoro, 2 -deoxy,
or 2 -O-methyl-modiﬁed counterparts [21–24].
3. Oligonucleotides Deliveryto the Brain
A crucial challenge for human glioma treatment is to
deliver drugs eﬀectively to invasive glioma cells residing in aJournal of Signal Transduction 3
Table 1: Advantages and disadvantages of microRNAs, siRNAs, and aptamers.
miRNAs siRNAs Aptamers
Advantages
(i) Chemically
synthesized (i) Chemically synthesized (i) Chemically synthesized
(ii) Small size (ii) Small size (ii) Small size
(iii) Suﬃciently stable (iii) Suﬃciently stable (iii) High target selectivity
(iv) Can be readily
chemically modiﬁed
(iv) Can be readily chemically
modiﬁed (iv) High aﬃnity
(v) Less immunogenic
than proteins
(v) Less immunogenic than
proteins (v) Suﬃciently stable
(vi) Already developed in
clinical trials
(vi) Can be readily chemically
modiﬁed
(vii) Less immunogenic than
proteins
(viii) Already developed in
clinic
Disadvantages
(i) Oﬀ-target eﬀects
(ii) Not yet developed
in clinical trials
Oﬀ-target eﬀects Only a few aptamers as
targeting agents for imaging
sanctuary within the central nervous system. Currently, it is
not practical to administer drugs to humans by invasive pro-
ceduressuchasintracerebroventricularinfusionorintracere-
bral injection, on the other hand, noninvasive intravenous
administrationofbrainneurodiagnosticorneurotherapeutic
agentsremainsachallengebecauseofthelowpermeabilityof
theBBB.Indeed,thesamemechanismsthatprotectthebrain
against intrusive chemicals can also frustrate therapeutic
interventions. BBB is constituted by endothelial cells of brain
capillaries which exhibit tight junctions that act as zippers
and close interendothelial pores, thereby restricting the free
movement of substances between the blood and the cerebral
interstitial ﬂuid [25]. More than 98% of small-sized drugs,
including oligonucleotides, do not cross the BBB. However,
diﬀerent strategies in which oligonucleotides are conjugated
to a transport vector that crosses the BBB, by means of
receptor-mediated transcytosis, have been reported. Several
recent papers describe the possibility to apply the brain
drug-targeting technology for the diagnosis or therapy of
many brain disorders [26–28]. Peptidomimetic monoclonal
antibodies (MAbs) that bind endogenous transport system
within the BBB, such as the insulin receptor, the transferrin
receptor (TfR), or the leptin receptor, have been used for
targetingneuropeptides,siRNAs,orantisenseagentsthrough
the BBB in vivo. Further, immunoliposomes have been gen-
erated carrying small hairpin RNA expression plasmids for
RNA interference (RNAi) eﬀect (see “siRNAs and gliomas”)
[29]. The immunoliposomes are then engineered with PEG,
which stabilizes their structure in circulation. The tissue
target speciﬁcity is given by conjugation of PEG residues
to MAbs that bind the endogenous transport system within
the BBB. This strategy presents a promising solution to
the DNA/RNA delivery obstacle. In this context, it appears
a challenging goal to reformulate the receptor-mediated
approach, and to substitute antibodies with synthetic small
aptamers,bydesigningnewandoriginalchimericmolecules.
As discussed below (“nucleic acid aptamers and gliomas”),
with ultimate objective of introducing therapeutic enzymes
across the BBB, aptamers against the extracellular domain of
the TfR have been selected [30].
Moreover, nanoparticles, which represent a very promis-
ing and innovative approach, have been also proposed to
eﬀectively and safely deliver drugs to the brain. Importantly,
they can be structurally modiﬁed to deliver a wide range
of therapeutics, improve delivery eﬃciency, and reduce
side eﬀects. Several types of nanoparticles such as linear
polymers, hyperbranched polymers, dendrimers, liposomes,
and micelles have been synthesized or engineered and
successfully developed as carriers for brain-speciﬁc drug
delivery, imaging, and diagnosis [31–35].
Once crossed the BBB, a safe and eﬃcient therapeutic
agentforgliomahastospeciﬁcallytargetcancercellsinorder
to avoid unwanted side eﬀects. In this regard, a promising
approach is based on the use of chimeric molecules consist-
ing of nucleic acid aptamers, directed against target proteins
speciﬁcally expressed on the surface of cancer cells, fused
to therapeutic siRNAs or miRNAs. The aptamers function
as speciﬁc recognition ligands to target cell population,
allowing the siRNA/miRNA therapeutic eﬀect only on this
subsetofcellsandthussubstantiallyreducingunwantedside-
eﬀects such as death of normal cells [36–38].
4. MicroRNAs andGliomas
MiRNAs are small noncoding RNA molecules (∼20–25 nt),
widely conserved through the evolution, that negatively
regulate gene expression at posttranscriptional level in
a sequence-speciﬁc manner. Following cellular processing
(illustratedinFigure 2),theybindaspeciﬁcsiteinthe3 UTR
of a target mRNA allowing the degradation of the messenger
ifthereisaperfectcomplementaritybetweenthemiRNAand
the binding site in the 3 UTR, or translational repression in
case of not perfect complementarity [39].4 Journal of Signal Transduction
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Figure 2:Schemeofmi/siRNAprocessingpathway.MiRNAsareﬁrsttranscribedintolongprimarymiRNAs(pri-miRNAs)bypolymeraseII
or,infewrarecases,bypolymeraseIII.PrimarymiRNAsarecleavedinthenucleusbyanRNAseIIIenzyme,Drosha,inducingtheconversion
into precursor miRNAs (pre-miRNAs). Pre-miRNAs are transported into the cytoplasm by exportin-5 and subsequently processed by Dicer,
a cytoplasmic endonuclease RNAse III enzyme, that generates a miRNA duplex. The functional strand of the mature miRNA is then
incorporated into the RISC (RNA-induced silencing complex), that mediates the degradation or the translation inhibition of the target
mRNA. For siRNA-mediated RNAi, double-stranded RNAs (dsRNAs) are chemically synthesized and then introduced into cell. dsRNAs are
directly cleaved into small double-stranded siRNAs by Dicer and then incorporated into the RISC leading to target mRNA degradation.
MiRNAs play an important role in cell cycle con-
trol, diﬀerentiation, proliferation, and apoptosis [40]a n d
provide attractive prognostic biomarkers and therapeutic
targets in diﬀerent kind of cancer including glioma (see
Table 2). Indeed, diﬀerent miRNA expression levels have
been observed in glioma tumors compared to surrounding
normal brain [41, 42].
MiR-21 is overexpressed in diﬀerent types of tumors,
including glioma [43–45]. In glioblastoma it acts as an
oncogene by suppressing apoptosis, thus suggesting that
impaired apoptotic pathway associated with miR-21 over-
expression could play an essential role in the pathogenesis
of this kind of tumors. It has been reported that miR-21
is able to target diﬀerent components of the p53, TGF-β
and mitochondrial apoptotic tumor-suppressive pathways in
glioblastoma.Indeed,proteinsthatstabilizep53levelsorthat
a c ta sp 5 3t r a n s c r i p t i o n a lc o f a c t o r s( s u c ha sp 6 3 ,j u n c t i o n
mediating and regulatory protein, topoisomerase I binding
arginine/serine rich, tumor protein p53 binding protein
2, death-domain associated protein, heterogeneous nuclear
ribonucleopreotein K), as well as TGFβR2/3 receptors, are
directly targeted by miR-21, resulting in a failed activation
of apoptosis and growth arrest [44]. In addition, miR-21
is able to regulate the invasive ability of glioma cells by
targeting RECK (reversion inducing cysteine rich protein)
and TIMP (tissue inhibitor of metalloproteinase-3), two
well characterized inhibitors of matrix metalloproteinases
proteins [46]. MiR-21 targets also programmed cell deathJournal of Signal Transduction 5
Table 2: MicroRNAs implicated in glioma.
miRNA Function Location Targets Cluster
Oncomir
miR-21 Inhibits apoptosis and promotes
invasion
Chr 17
intergenic
TP53BP2 [44]
DAXX [44]
HNRNPK [44]
RECK [46]
TIMP3[46]
PDC4 [47]
miR-221 Promotes proliferation and
invasion Chr X intergenic
PTPμ [48]
P27 [49] miR-221/222
miR-222 Promotes proliferation and
invasion Chr X intergenic PTPμ [48]
P27 [49] miR-221/222
miR-9 Inhibits neural diﬀerentiation
and induce proliferation
Chr 9
sense
CAMTA1 [50]
REST [52]
Tumor
suppressor
miR-124
Induces G0/G1 cell cycle arrest;
induce diﬀerentiation of adult
mouse neural stem cells
Chr 8
sense CDK6 [53]
miR-137
Induces G0/G1 cell cycle arrest;
induces diﬀerentiation of adult
mouse neural stem cells
Chr 1
sense CDK6 [53] miR-137/2682
miR-7
Tumor suppressor; suppresses
EGFR expression and
independently inhibits Akt
pathway
Chr 9
sense EGFR [55]
miR-128 Inhibits cell proliferation by
targeting Bmi-1 and E2F3a
Chr 2
sense
E2F3A
BMI1 [56]
miR-181 Is downregulated and associated
with poor prognosis
Chr 9
Sense antisense unknown miR-181a/b
4, a tumor suppressor protein, involved in the inhibition
of the translation and cell proliferation [47]. Remark-
ably, due to the high number of important proteins with
tumor suppressive functions targeted by miR-21, it could
be considered a major mediator in the pathogenesis of
glioblastoma. Accordingly, its targeted downregulation in
the more aggressive human glioblastoma, could represents a
great therapeutic challenge.
Like miR-21, the cluster miR-221/222 was shown to be
o v e r e x p r e s s e di nd i ﬀerent cancers, including glioma [41,
45, 48]. The importance of the miR-221/222 cluster lies
in the fact that it is able to impair cell cycle control
leading to an increase of proliferation rate by targeting p27
[49]. Interestingly, it has been observed that CDK4 (cyclin-
dependent kinase 4) is able to induce the expression of
the miR-221/222, which in turn contributes to keep low
p27proteinlevels,thusstimulatingcontinuousproliferation.
Recently, it has been reported that miR-221 and miR-222
could contribute to glioma invasiveness targeting protein
tyrosine phosphatase μ, a tyrosine phosphatase protein that
suppresses cell migration and that is downregulated in
glioblastoma [48].
Furthermore, miR-9 has been found highly expressed
in cancer stem cells obtained from primary astrocytic
glioblastomas [50] and in primary brain tumors [51]. This
miRNA downregulates the RE1-silencing transcription fac-
tor (REST), promoting neural diﬀerentiation. REST, in turn,
is able to repress miR-9, thus creating a negative feedback
loop between a microRNA and a transcriptional regulator
[52]. In addition miR-9 downregulates the tumor suppressor
CAMTA1 (calmodulin binding transcription activator 1)
which induces the expression of the antiproliferative Natri-
u r e t i cP e p t i d et y p eA[ 50].
On the other hand, several miRNAs have been reported
to be underexpressed in glioblastoma samples compared to
surrounding normal brain. MiR-124 and miR-137 represent
two of the most signiﬁcantly downregulated miRNAs in
glioblastoma tissues [41]. Both of these two miRNAs directly
target CDK6 that regulates cell cycle progression and diﬀer-
entiation [53]. MiR-7 is poorly expressed in human glioma
tissues [54] and its overexpression in cultured glioma cell
linesinducesareductionofviabilityandtheabilitytoinvade.
This can be explained by the fact that the miR-7 is able to
modulate the expression of epidermal growth factor receptor
(EGFR)withtheconsequentsuppressionofAktactivity[55].
Another example is miR-128, that belongs to the class
of brain-speciﬁc microRNAs [55]. As compared to normal
tissue, the levels of this miRNA are extremely low in glioblas-
tomas and, even at lesser degree, in low-grade gliomas
[41, 56]. MiR-128 is able to decrease the expression of E2F
transcription factor 3 (E2F3a) and of the BMI1 polycomb
ring ﬁnger oncogene (Bmi-1) [56], and this may explain the
ability of this miRNA to decrease cell proliferation both in
vitro and in vivo.6 Journal of Signal Transduction
TwostudieshavereportedadownregulationofmiR-181a
and miR-181b in samples of human glioma cell lines [57].
The expression of these two miRNAs in glioma cells leads
to the inhibition of growth and invasion, with induction of
apoptosis [57]. However, molecular targets of these miRNAs
remain still unknown.
Moreover, a recent report indicates that the expression
proﬁle of a set of seven miRNAs (miR-21, miR-128, miR-
132,miR-134,miR-155,miR-210,andmiR-409-5p)allowsto
discriminate between oligodendroglioma and glioblastoma
[42]. Further, the alteration of miRNAs expression proﬁle in
gliomas has been found associated to their high resistance to
the most commonly used antineoplastic agents [58–60], thus
opening new prospective for glioma treatment.
5. siRNAs and Gliomas
siRNAs are synthetic double-stranded RNA molecules (∼
20–25nt) that inhibit gene expression at posttranscriptional
level in a sequence speciﬁc manner. As illustrated in Figure 2,
the processing of siRNAs converges into the same molecular
pathway of miRNAs mediating gene silencing [61].
SiRNAshavebeensuccessfullyappliedtothetreatmentof
several human diseases [62] and in recent years this class of
molecules has shown a great therapeutic potential for glioma
[63].
To date, the most promising siRNA therapeutic appli-
cation in glioma is represented by an interference RNA
targeting tenascin-C (TN-C) [64, 65]. TN-C is an extra-
cellular matrix protein that is overexpressed in diﬀerent
cellularprocessesincludingtumorgrowth,anditsexpression
correlates with a higher tumor grade in human glioma [66].
In a group of 46 patients aﬀected by brain tumor [65],
a dsRNA (ATN-RNA) complementary to the sequence of
TN-C mRNA was administrated during surgery directly into
neoplastic brain inﬁltration that could not be removed.
Remarkably, the inhibition of TN-C synthesis induced
growthtumordelaywithimprovementsinsurvivalandqual-
ityoflife.Currently,thisistheonlyexampleofclinicalsetting
for siRNA-based therapies in glioma. However, a vast and
increasing number of siRNAs targeting important molecular
pathways, such as those involved in apoptosis, proliferation,
cell invasion/migration, angiogenesis, and metabolism, has
been studied and could represent good candidates for
malignant glioma treatment (see [67] as review).
One particularly important drawback for the clinical
development of siRNA therapeutics is the necessity of an
appropriate and high eﬃciency in vivo delivery strategy to
guarantee intracellular target accessibility and speciﬁcity of
action. Diﬀerent strategies for safe and eﬃcacious siRNAs
delivery to the brain have been proposed [68, 69]a s
summarized in Table 3. For example, a plasmid encoding a
short hairpin RNA targeting the human EGFR was delivered
to the brain through encapsulation in pegylated immunoli-
posomes(PILs),conjugatedwithtwomonoclonalantibodies
allowing for the transport [29]. Indeed, the ﬁrst antibody
directed against the transferrin receptor enabled PILs to
cross the BBB by transcytosis. Then, the antibody against
Table 3: Strategies for siRNA delivery across the BBB.
Delivery system siRNA target Ref.
Pegylated immunoliposomes EGFR [29]
siRNA/TfR antibody complexes by
biotin-streptavidin bridge Luciferase [65]
Polyethylenimine/siRNA complexes Pleiotrophin [66]
Nanoparticles/siRNA complexes HIF-1α [68]
Recombinant adeno-associated virus Hec1 [69]
Herpes simplex virus 1 EGFR; Rad51 [70, 71]
Lentiviral vectors shBcl-2 and
S-TRAIL [73]
the insulin receptor permits to speciﬁcally target PILs on
glioma cells. Remarkably, weekly intravenous administration
of PILs in mice bearing intracranial brain cancer caused
an increase of survival. Furthermore, a directly coupling to
TfR antibody via streptavidin-biotin linker was successfully
applied for siRNA targeting to brain [70]. Other systems for
siRNA delivery to brain include polyethyleneimine/siRNA
complexes[71],coatednanoparticlesresemblinglow-density
lipoproteins [72, 73], and viral vector [74–78].
6. NucleicAcid AptamersandGliomas
Aptamers are an emerging class of small (8–15kDa) thera-
peutic nucleic acid molecules that unlike siRNAs/miRNAs,
act by directly binding the target without interfering with
its expression. They are generated by an in vitro procedure
named SELEX that allows to isolate aptamers from combina-
torial libraries through reiterated rounds of: (1) incubation
of the library with the target molecule; (2) partition of
unbound oligonucleotides from bound sequences; (3) disso-
ciation of the aptamer-target complexes (4) ampliﬁcation of
the nucleic acids library enriched in sequences that bind to
the target (see Figure 3). At the end of the selection process,
the PCR products are cloned and sequenced and the best
binding sequences are identiﬁed.
SELEX approach has been initially developed to generate
aptamers against puriﬁed proteins and more recently the
method has been extended to complex targets, including
whole living cells, with the advantage of enabling the
identiﬁcation of aptamers that bind cell-surface speciﬁc
antigens in their proper environments [36, 79]. To date, the
list of aptamers generated against important diagnostic and
therapeutic targets is growing rapidly and many of them are
alreadyinclinicaltrialsfordiﬀerenthumandiseases[80–82].
As discussed above, TN-C is a very interesting target in
glioma and aptamers directed against this protein have been
generatedbyanapproachbasedonacrossoverSELEXexper-
iment that involves crossing from cell-SELEX to protein-
SELEX [83, 84]. Although, they have not been developed in
therapy, they are very attractive tools for imaging. Indeed
an RNA aptamer against TN-C, named TTA1, has been
conjugated with 99mTc and enables a clear imaging of TN-C-
positive tumors in murine xenograft models of glioblastoma
[85]. Another promising aptamer as diagnostic tool forJournal of Signal Transduction 7
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Figure 3: Scheme of SELEX technology. The starting point of the SELEX technology for aptamers production is the synthesis of a high
complexity ssDNA/RNA library containing a variable region ﬂanked by two constant regions. At each SELEX round the library is incubated
with the target molecule and bound aptamers are recovered and ampliﬁed. At the end of the selection process, the PCR products are cloned
and sequenced.
glioma has been generated against transformed endothelial
cells (EC) [86]. This aptamer was found to bind the rat
homologue of mouse protein pigpen that regulates EC
proliferation and is involved in angiogenesis. It has been
shownthattheanti-pigpenaptamerisabletoselectivelylabel
microvesselsofratbrainglioblastomabutnotthevasculature
of the normal rat brain and thus, it can be used to analyze
pathological angiogenesis of glioblastoma.
Given the glioma complex cellular heterogeneity,
the development of eﬀective diagnostic and therapeutic
approaches largely relies on the possibility to distinguish
between even close tumor types with high accuracy. In
this perspective, the development of the SELEX technology
against living cells has a great potential. Indeed, this strategy
allows to select aptamers able to speciﬁcally recognize
diseased cells or discriminate diﬀerent cell phenotypes.
We have developed a diﬀerential cell-SELEX approach to
isolate RNA aptamers against cell surface glioma-speciﬁc
targets [87]. In such approach, that is a variant of cell-Selex
that we used to generate aptamers against Ret [88], we
performed iterative positive selection steps with human
malignant U87MG cells, each preceded by counter-selection
with non tumorigenic T98G cells. Seven diﬀerent aptamers
speciﬁcally recognize multiple targets on U87MG cells,
which constitute a signature that might distinguish high-
from low-or non-tumorigenic glioma cell lines and primary
cultures.Furthermore,fouroutofthesevenaptamersinhibit
speciﬁc intracellular signaling pathways [87].
A key target for glioma treatment is the EGFR that
is highly expressed in diﬀerent types of cancer including
glioma [89]. Recently, unmodiﬁed RNA-aptamers have been
selected against the puriﬁed extracellular domain of EGFR.
The aptamers have been conjugated to gold nanoparticles
to speciﬁcally deliver these nanoparticles to EGFR-positive
cancer cells by receptor-mediated endocytosis [90]. Further,
glass surfaces functionalized with anti-EGFR aptamers have
been used to capture with high sensitivity and speciﬁcity
human and murine glioma cells expressing EGFR [91]. More
recently, in order to improve in vivo aptamers stability, the
same authors performed a new selection against a puriﬁed
Fc-EGFR fusion protein using a 2 -F-Py RNA pool. They
showed that one of the selected aptamers, E07, bound to
the receptor as well as to A431 cells expressing EGFR,
hampering EGF-dependent receptor autophosphorylation in
vitro [92]. In addition, by cell-SELEX we generated a 2 -
F Py-RNA aptamer that binds to EGFR with a binding
constant of 10nM. This aptamer inhibits EGFR-mediated
signal pathways causing selective apoptotic cell death even
in cells that are resistant to the most frequently used
EGFR-inhibitors, as geﬁtinib and cetuximab. Remarkably,
combined treatment with cetuximab and the aptamer shows
clear synergy in inducing apoptosis and inhibiting tumor
growth in a mouse xenograft model of human cancer, thus
resulting in the ﬁrst report of an anti-EGFR aptamer whose
activity has been proved in vivo [93].
Activateddeletion variantEGFRvIIIis themost common
EGFR mutation found in malignant gliomas. RNA aptamers
have been recently generated against the histidine-tagged
extracellular domain of EGFRvIII using an Escherichia coli
expression system. These aptamers do not bind the protein8 Journal of Signal Transduction
expressed by eukaryotic cells likely because of glycosylation
of the receptor [94]. Hence, EGFRvIII aptamers were
transfected, where they act by binding the newly synthesized
EGFRvIII and inhibit its glycosylation thus increasing the
percentage of cells undergoing apoptosis.
Apart from the utility of aptamers as ligands of targets
important for glioma, another promising application of
aptamers against cell surface molecules is to employ their
excellent targeting properties to speciﬁcally deliver therapeu-
tic agents to the brain. Recently, with ultimate objective of
introducing therapeutic enzymes across the BBB, aptamers
against the extracellular domain of the TfR have been
selected. These molecules were successfully used to deliver
diﬀe r e n tr e a g e n t st om o u s eﬁ b r o b l a s tc e l l s[ 30]a n dc a n
potentially be used, as alternative to antibodies, to design
new and original chimeric molecules able to across the
BBB through receptor-mediated transcytosis. In addition,
aptamers showed an excellent potential as reagents for the
delivery of miRNAs and siRNAs to a given target cell or
tissue [36–38]. Even if to date there are no results for
glioma, Giangrande’s and Rossi’s groups developed diﬀerent
innovative and eﬀective chimeric molecules in which siRNAs
were conjugated to aptamers targeting the prostate-speciﬁc
membrane antigen or the HIV glycoprotein gp120, for
speciﬁc aptamer-mediated siRNA delivery [95–99].
7. Conclusions
As discussed above, the interest for miRNAs, siRNAs and
aptamers as innovative approaches for glioma treatment
is rapidly increasing. Even if their clinical development is
still being realized, oligonucleotides have several important
advantages over traditional drugs and hold an extraordinary
potential for glioma diagnosis and therapy. However, as
with any novel therapeutic tool, further studies are required
for their eﬀective translation into clinic especially for what
it concern glioma-speciﬁc tumor targeting. As discussed
in this paper to address this issue, a highly intriguing
approach could be the generation of chimeric molecules in
which aptamers, directed against speciﬁc cell surface target
proteins, are fused with therapeutic siRNAs or miRNAs.
Diﬀerent approaches for aptamers-siRNA conjugation
have been developed [36–38] and recently Archemix Corp.,
a leading biopharmaceutical company in the development
of aptamers as therapeutics, started a collaboration with
miRagen Therapeutics Inc., a biopharmaceutical company
focused on developing innovative microRNA-based ther-
apeutics for cardiovascular and muscle disease, for the
development of conjugated aptamer-microRNA molecules
capable of intracellular delivery and subsequent microRNA
targeting.
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